EFFECTS OF KRN23, AN ANTI-FGF23 ANTIBODY, IN PATIENTS WITH TUMOR-INDUCED OSTEOMALACIA OR EPIDERMAL NEVUS SYNDROME-ASSOCIATED OSTEOMALACIA: INTERIM RESULTS FROM A PHASE 2 STUDY

被引：0
|
作者：
Carpenter, T. [1 ]
Miller, P. D. [2 ]
Weber, T. [3 ]
Peacock, M. [4 ]
Ruppe, M. [5 ]
Insogna, K. [1 ]
Luca, D. [6 ]
Skrinar, A. [6 ]
San Martin, J. [6 ]
de Beur, S. Jan [7 ]
机构：
[1] Yale Univ, Sch Med, New Haven, CT USA
[2] Colorado Ctr Bone Res, Lakewood, CO USA
[3] Duke Univ, Durham, NC USA
[4] Indiana Univ Sch Med, Indianapolis, IN 46202 USA
[5] Houston Methodist Hosp, Houston, TX USA
[6] Ultragenyx Pharmaceut Inc, Novato, CA USA
[7] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
来源：
OSTEOPOROSIS INTERNATIONAL | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P531
引用
收藏
页码：S337 / S338
页数：2
相关论文
共 15 条
  • [1] Effects of Burosumab (KRN23), a Human Monoclonal Antibody to FGF23, in Patients with Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS).
    De Beur, Suzanne Jan
    Miller, Paul D.
    Weber, Thomas J.
    Peacock, Munro
    Ruppe, Mary D.
    Insogna, Karl
    Luca, Diana
    Theodore-Oklota, Christina
    San Martin, Javier
    Carpenter, Thomas
    JOURNAL OF BONE AND MINERAL RESEARCH, 2017, 32 : S280 - S280
  • [2] Tumor-Induced Osteomalacia: Treatment Progress Using Burosumab, an Anti-FGF23 Monoclonal Antibody
    Whyte, Michael P.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2021, 36 (04) : 625 - 626
  • [3] The Effect of Burosumab (KRN23), a Fully Human Anti-FGF23 Monoclonal Antibody, on Osteomalacia in Adults with X-Linked Hypophosphatemia (XLH)
    Insogna, Karl L.
    Rauch, Frank
    Kamenicky, Peter
    Ito, Nobuaki
    Kubota, Takuo
    Nakamura, Akie
    Zhang, Lin
    Mealiffe, Matt
    San Martin, Javier
    Portale, Anthony A.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2018, 33 : 122 - 122
  • [4] EFFECT OF BUROSUMAB (KRN23), A FULLY HUMAN ANTI-FGF23 MONOCLONAL ANTIBODY, ON OSTEOMALACIA IN ADULTS WITH X-LINKED HYPOPHOSPHATEMIA (XLH)
    Kamenicky, P.
    Insogna, K.
    Ito, N.
    Kubota, T.
    Nakamura, A.
    Mealiffe, M.
    San Martin, J.
    Portale, A.
    OSTEOPOROSIS INTERNATIONAL, 2019, 30 : S416 - S417
  • [5] EFFECTS OF BUROSUMAB, AN ANTI-FGE23 ANTIBODY, IN PATIENTS WITH TUMOR-INDUCED OSTEOMALACIA: RESULTS FROM AN ONGOING PHASE 2 STUDY
    Ito, Nobuaki
    Imanishi, Yasuo
    Takeuchi, Yasuhiro
    Takahashi, Yutaka
    Rhee, Yumie
    Shin, Chan Soo
    Kanda, Hironori
    Fukumoto, Seiji
    JOURNAL OF BONE AND MINERAL RESEARCH, 2018, 33 : 300 - 300
  • [6] BUROSUMAB (ANTI-FGF23 MONOCLONAL ANTIBODY) IN THE TREATMENT OF A PATIENT WITH RECURRENT TUMOR INDUCED OSTEOMALACIA.
    Crotti, C.
    Zucchi, F.
    Messa, P.
    Caporali, R.
    Varenna, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1758 - 1758
  • [7] Effect of krn23, a Fully Human anti-fgf23 Monoclonal Antibody, on Rickets in Children with X-linked Hypophosphatemia (xlh): 40-week Interim Results from a Randomized, Open-label Phase 2 Study
    Portale, Anthony A.
    Imel, Eric
    Boot, Annemieke
    Hogler, Wolfgang
    Linglart, Agnes
    Padidela, Raja
    van't Hoff, William
    Whyte, Michael
    San Martin, Javier
    Carpenter, Thomas
    PEDIATRICS, 2018, 141
  • [8] Effect of KRN23, a Fully Human Anti-FGF23 Monoclonal Antibody, on Rickets in Children with X-linked Hypophosphatemia (XLH): 40-week Interim Results from a Randomized, Open-label Phase 2 Study
    Linglart, Agnes
    Carpenter, Thomas
    Imel, Erik
    Boot, Annemieke
    Hogler, Wolfgang
    Padidela, Raja
    Van't Hoff, William
    Whyte, Michael
    Chen, Chao-Yin
    Skrinar, Alison
    Agarwal, Sunil
    Martin, Javier San
    Portale, Anthony
    HORMONE RESEARCH IN PAEDIATRICS, 2016, 86 : 33 - 33
  • [9] Effect of KRN23, a Fully Human Anti-FGF23 Monoclonal Antibody, on Rickets in Children with X-Linked Hypophosphatemia (XLH): 40-Week Interim Results from a Randomized, Open-Label Phase 2 Study
    Carpenter, T.
    Hogler, W.
    Imel, E.
    Boot, A.
    Linglart, A.
    Padidela, R.
    van't Hoff, W.
    Whyte, M.
    Chen, C.
    Skrinar, A.
    San Martin, J.
    Portale, A.
    HORMONE RESEARCH IN PAEDIATRICS, 2016, 86 : 19 - 20
  • [10] Cinacalcet is associated with decreased serum FGF-23 and improved phosphorous homeostasis in patients with tumor-induced osteomalacia.
    Geller, JL
    Cutler, C
    Kelly, MH
    Adams, JS
    Collins, MT
    JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (09) : S177 - S177
12